Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures

This prospective multicenter observational study will evaluate the effectiveness, safety, tolerability, and impact on quality of life of eslicarbazepine in adults with focal-onset seizures in routine clinical practice. Participants will include newly diagnosed patients and patients previously treated with carbamazepine or oxcarbazepine who have inadequate seizure control or intolerable adverse effects. Treatment with eslicarbazepine will be initiated or changed at the discretion of the treating physician in accordance with routine clinical practice. Participants will be followed for 3 months.

Inclusion Criteria: * Adult patients (aged at least 18 years) with diagnosed partial-onset seizures. * Newly diagnosed (treatment-naïve) or previously treated with Carbamazepine or Oxcarbazepine and inadequately controlled or intolerant. * Patient or Legal Representative is willing and able to provide informed consent, or, in the absence of a legal representative, an Independent Healthcare Professional provides authorization for patient enrolment. Exclusion Criteria: * Any hypersensitivity to Eslicarbazepine. * Female patients who are pregnant or lactating. * Patients who have a contraindication to the medicine or any component of prescribed therapy.